Methylprednisolone, valacyclovir, or the combination for vestibular neuritis

Area of Science:

• Neurology
• Otolaryngology
• Infectious Diseases

Background:

• Vestibular neuritis, a common cause of peripheral vestibular vertigo, is often linked to herpes simplex virus type 1 reactivation.
• Current treatments explore corticosteroids and antiviral agents to improve patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of methylprednisolone and valacyclovir, alone or in combination, for treating acute vestibular neuritis.
• To determine the impact of these treatments on the recovery of peripheral vestibular function.

Main Methods:

• A prospective, randomized, double-blind, two-by-two factorial trial was conducted.
• 141 patients with acute vestibular neuritis were assigned to placebo, methylprednisolone, valacyclovir, or combination therapy.
• Vestibular function was assessed using caloric irrigation and the vestibular paresis formula at symptom onset and 12 months post-treatment.

Main Results:

• Methylprednisolone treatment resulted in a significantly greater improvement in peripheral vestibular function compared to placebo (62.4% vs. 39.6%).
• Valacyclovir showed no significant improvement in vestibular function compared to placebo (36.0% vs. 39.6%).
• The combination of methylprednisolone and valacyclovir was not superior to methylprednisolone alone.

Conclusions:

• Methylprednisolone monotherapy significantly enhances the recovery of peripheral vestibular function in patients diagnosed with vestibular neuritis.
• Valacyclovir does not demonstrate a significant therapeutic effect on vestibular function recovery in vestibular neuritis.